<VariationArchive VariationID="1699267" VariationName="NM_000061.3(BTK):c.1257del (p.Lys420fs)" VariationType="Deletion" Accession="VCV001699267" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-23" DateCreated="2022-08-08" MostRecentSubmission="2024-07-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1691641" VariationID="1699267">
      <GeneList>
        <Gene Symbol="BTK" FullName="Bruton tyrosine kinase" GeneID="695" HGNC_ID="HGNC:1133" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101349450" stop="101390796" display_start="101349450" display_stop="101390796" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100604434" stop="100641211" display_start="100604434" display_stop="100641211" Strand="-" />
          </Location>
          <OMIM>300300</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BTK">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000061.3(BTK):c.1257del (p.Lys420fs)</Name>
      <CanonicalSPDI>NC_000023.11:101356875:CCC:CC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101356876" stop="101356876" display_start="101356876" display_stop="101356876" variantLength="1" positionVCF="101356875" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100611864" stop="100611864" display_start="100611864" display_stop="100611864" variantLength="1" positionVCF="100611863" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>K420fs</ProteinChange>
      <ProteinChange>K454fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100611866del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100611866del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101356878del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101356878del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009616.1" sequenceAccession="NG_009616" sequenceVersion="1" change="g.34349del">
            <Expression>NG_009616.1:g.34349del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000061.3" sequenceAccession="NM_000061" sequenceVersion="3" change="c.1257del" MANESelect="true">
            <Expression>NM_000061.3:c.1257del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000052.1" sequenceAccession="NP_000052" sequenceVersion="1" change="p.Lys420fs">
            <Expression>NP_000052.1:p.Lys420fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287344.2" sequenceAccession="NM_001287344" sequenceVersion="2" change="c.1359del">
            <Expression>NM_001287344.2:c.1359del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274273.1" sequenceAccession="NP_001274273" sequenceVersion="1" change="p.Lys454fs">
            <Expression>NP_001274273.1:p.Lys454fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287345.2" sequenceAccession="NM_001287345" sequenceVersion="2" change="c.1038+1498del">
            <Expression>NM_001287345.2:c.1038+1498del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_128" sequenceAccession="LRG_128">
            <Expression>LRG_128:g.34349del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_128t1" sequenceAccession="LRG_128t1">
            <Expression>LRG_128t1:c.1257del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2147428293" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000061.3(BTK):c.1257del (p.Lys420fs) AND X-linked agammaglobulinemia" Accession="RCV002273124" Version="3">
        <ClassifiedConditionList TraitSetID="3110">
          <ClassifiedCondition DB="MedGen" ID="C0221026">X-linked agammaglobulinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-02-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-02-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-08-08" MostRecentSubmission="2024-07-23">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">14974089</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31803177</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3110" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="39" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, Bruton tyrosine kinase</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Agammaglobulinemia, BTK</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BTK-deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">X-linked agammaglobulinemia</ElementValue>
                <XRef ID="X-linked+agammaglobulinemia/7543" DB="Genetic Alliance" />
                <XRef ID="65880007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bruton-type agammaglobulinemia</ElementValue>
                <XRef ID="MONDO:0010421" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Bruton's agammaglobulinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AGAMMAGLOBULINEMIA, X-LINKED, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">IMMUNODEFICIENCY 1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">XLA</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AGMX1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">IMD1</ElementValue>
                <XRef Type="MIM" ID="300755" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1033" />
                <XRef ID="1033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. S pneumoniae and H influenzae are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics.</Attribute>
                <XRef ID="NBK1453" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301626</ID>
                <ID Source="BookShelf">NBK1453</ID>
              </Citation>
              <XRef ID="229717" DB="Orphanet" />
              <XRef ID="47" DB="Orphanet" />
              <XRef ID="C0221026" DB="MedGen" />
              <XRef ID="MONDO:0010421" DB="MONDO" />
              <XRef Type="MIM" ID="300755" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5003572" SubmissionDate="2024-07-18" DateLastUpdated="2024-07-23" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000061_2_BTK_c_1257delG" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002557766" DateUpdated="2024-07-23" DateCreated="2022-08-08" Type="SCV" Version="2" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">14974089</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31803177</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with X-linked agammaglobulinemia 1 (MIM#300755). (I) 0109 - This gene is associated with X-linked recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. NMD-predicted variants in this gene are a well-established cause of disease (ClinGen, PMID: 14974089) (SP) 0803 - This variant has limited previous evidence of pathogenicity in unrelated individuals. One affected family has been reported with this variant in the literature (PMID: 31803177). (SP) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">X-linked recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BTK" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_15182</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000061.2:c.1257delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="300755" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_32</SubmissionName>
          <SubmissionName>submission_45</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5003572" TraitType="Disease" MappingType="XRef" MappingValue="300755" MappingRef="OMIM">
        <MedGen CUI="C0221026" Name="X-linked agammaglobulinemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

